What topics does this cannabis study cover?

This study covers research on: Terpenes, Endocannabinoid.

Where was this research published?

Published in Plants (Basel, Switzerland) on July 11, 2026.

Cannabis compounds beyond cannabinoids may shape whole-plant effects

Q: What did this Review find?

The review identified **12 eligible studies** from an initial **187 articles**, highlighting how limited the published research on cannabis’s *non-cannabinoid phytochemicals* remains.

The Pharmacological Activity of Non-Cannabinoid Phytochemicals in Cannabis sativa L.: A Systematic Review.

Plants (Basel, Switzerland) • July 11, 2026 • Review • Highly Relevant

🤖

AI Summary

This systematic review examines the pharmacological potential of non-cannabinoid phytochemicals in Cannabis sativa, including terpenes, flavonoids, phenolic compounds, and alkaloids. The authors searched major scientific databases and screened 187 published articles from January 2010 through May 2025, selecting 12 studies that met their criteria. The review indicates that these compounds may contribute substantially to cannabis’s biological activity, rather than cannabinoids being the only source of therapeutic potential.

The strongest evidence discussed involved terpenes and flavonoids, including possible synergistic interactions with cannabinoids through mechanisms such as the entourage effect. However, the abstract does not report clinical outcome measurements or quantitative evidence of benefit in cannabis users. The authors emphasize that translation into treatments remains limited by inconsistent plant chemistry, regulatory barriers, and inadequate analytical methods. For consumers, the findings suggest that whole-plant effects may depend on more than THC or CBD content—but they do not yet establish that specific non-cannabinoid compounds reliably improve health outcomes.

💡 Key Findings

The review identified 12 eligible studies from an initial 187 articles, highlighting how limited the published research on cannabis’s non-cannabinoid phytochemicals remains.

High

80%

Terpenes and flavonoids were the best-characterized non-cannabinoid groups and showed reported synergistic interactions that may support the entourage effect.

Good

70%

Clinical translation remains limited because of challenges involving standardization, regulation, and well-defined analytical methods.

High

85%

The review concludes that non-cannabinoid compounds are important contributors to the pharmacological complexity of Cannabis sativa and warrant further study for whole-plant drug development.

High

80%

📄 Original Abstract

Cannabis sativa (C. sativa) is widely recognized for its therapeutic potential, historically attributed to its cannabinoid content. Some of the phytocannabinoid compounds of C. sativa are mediated through interactions with the endocannabinoid system, while some are able to modulate the interaction between cannabinoids and the endocannabinoid system. Additionally, the non-cannabinoid group exhibits a broad range of bioactive potential, also displaying pharmacological actions. However, the non-cannabinoid fraction of the plant has not been extensively studied. This review emphasizes the emerging pharmacological importance of non-cannabinoid phytochemicals such as terpenes, flavonoids, phenolic compounds, and alkaloids found within C. sativa. Scopus, Google Scholar, and PubMed were utilized as databases to search for relevant published literature. The search employed the keywords such as "Cannabis sativa phytochemicals, non-cannabinoid compounds of Cannabis sativa, pharmacological activity of non-cannabinoid compounds of Cannabis sativa". The total number of published articles initially retrieved between January 2010 and May 2025 was 187. From these, only 12 articles were selected according to the inclusion and exclusion criteria. The review highlights the structural diversity and functional significance of non-cannabinoid constituents. Terpenes and flavonoids were particularly well-characterized, with demonstrated synergistic interactions that enhanced therapeutic efficacy via mechanisms like the "entourage effect." Despite promising preclinical findings, the clinical translation of these compounds remains limited due to challenges in standardization, regulatory barriers, and a lack of well-defined analytical methods. This review concludes that non-cannabinoid phytochemicals are integral to the pharmacological complexity of C. sativa and warrant further investigation as potential candidates for drug development, especially in formulations that aim to optimize whole-plant therapeutic effects.

Paper Type

📚 Review

Publication

Journal: Plants (Basel, Switzerland)
Published: July 11, 2026
PMID: 42514510
DOI: 10.3390/plants15142142

Authors (3)

Olakunle Sanni Department of Clinical Pharmacology and Therapeutics, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria 0204, South Africa.
Modupe Olufunmilayo Ogunrombi Department of Clinical Pharmacology and Therapeutics, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria 0204, South Africa.
Chikwelu Lawrence Obi Department of Biology and Environmental Sciences, School of Science and Technology, Sefako Makgatho Health Sciences University, Pretoria 0204, South Africa.